Amicus Therapeutics, Inc. (FOLD) Earnings History
Annual and quarterly earnings data from 2005 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 90.0% | 4.7% | -10.6% |
| 2023 | 90.7% | -19.3% | -38.0% |
| 2022 | 88.3% | -64.4% | -71.9% |
| 2021 | 88.7% | -67.6% | -82.0% |
| 2020 | 88.1% | -94.7% | -106.1% |
Download Data
Export FOLD earnings history in CSV or JSON format
Free sign-in required to download data
Amicus Therapeutics, Inc. (FOLD) Earnings Overview
As of February 28, 2026, Amicus Therapeutics, Inc. (FOLD) reported trailing twelve-month net income of -$14M, reflecting +0.6% year-over-year growth. The company earned $-0.05 per diluted share over the past four quarters, with a net profit margin of -0.1%.
Looking at the long-term picture, FOLD's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2009.
Amicus Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), FOLD has outperformed on profitability metrics. Compare FOLD vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
20 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$56M | +63.0% | $25M | $-0.18 | -10.6% | 4.7% |
| 2023 | -$152M | +35.9% | -$77M | $-0.51 | -38.0% | -19.3% |
| 2022 | -$237M | +5.5% | -$212M | $-0.82 | -71.9% | -64.4% |
| 2021 | -$250M | +9.5% | -$206M | $-0.92 | -82.0% | -67.6% |
| 2020 | -$277M | +22.3% | -$247M | $-1.07 | -106.1% | -94.7% |
| 2019 | -$356M | -2.1% | -$304M | $-1.48 | -195.6% | -166.8% |
| 2018 | -$349M | -22.9% | -$329M | $-1.88 | -382.5% | -360.3% |
| 2017 | -$284M | -42.0% | -$442M | $-1.85 | -769.0% | -1196.8% |
| 2016 | -$200M | -51.4% | -$182M | $-1.49 | -4034.7% | -3668.6% |
| 2015 | -$132M | -91.7% | -$130M | $-1.20 | - | - |
See FOLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FOLD Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare FOLD vs AGIO
See how FOLD stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is FOLD growing earnings?
FOLD EPS of $-0.05 reflects slowing growth at +0.6%, below the 5-year CAGR of N/A. TTM net income is $-14M. Expansion rate has moderated.
What are FOLD's profit margins?
Amicus Therapeutics, Inc. net margin is -0.1%, with operating margin at +0.0%. Below-average margins reflect competitive or cost pressures.
How consistent are FOLD's earnings?
FOLD earnings data spans 2005-2024. The current earnings trend is +0.6% YoY. Historical data enables comparison across business cycles.